Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Income (2016 - 2025)

Ptc Therapeutics has reported Net Income over the past 14 years, most recently at -$1.4 billion for Q4 2025.

  • Quarterly results put Net Income at -$1.4 billion for Q4 2025, down 1384.77% from a year ago — trailing twelve months through Dec 2025 was -$555.9 million (down 42.58% YoY), and the annual figure for FY2025 was -$555.9 million, down 42.58%.
  • Net Income for Q4 2025 was -$1.4 billion at Ptc Therapeutics, down from $15.9 million in the prior quarter.
  • Over the last five years, Net Income for PTCT hit a ceiling of $866.6 million in Q1 2025 and a floor of -$1.4 billion in Q4 2025.
  • Median Net Income over the past 5 years was -$113.8 million (2021), compared with a mean of -$70.8 million.
  • Peak annual rise in Net Income hit 1046.28% in 2025, while the deepest fall reached 1384.77% in 2025.
  • Ptc Therapeutics' Net Income stood at $344.5 million in 2021, then tumbled by 159.1% to -$203.6 million in 2022, then soared by 408.94% to $629.0 million in 2023, then tumbled by 114.71% to -$92.5 million in 2024, then tumbled by 1384.77% to -$1.4 billion in 2025.
  • The last three reported values for Net Income were -$1.4 billion (Q4 2025), $15.9 million (Q3 2025), and -$64.8 million (Q2 2025) per Business Quant data.